MedTrace Logo

Intravitreal Aflibercept Injection for Radiation Retinopathy

NCT01579760 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2019-04-25

No results posted yet for this study

Summary

The purpose of this study is to assess the safety of intravitreal aflibercept injection - in the treatment of macular edema associated with retinopathy secondary to previous radiation therapy.

Conditions

  • Radiation Retinopathy
  • Macular Edema

Interventions

DRUG

Aflibercept every 2 months

2.0 mg aflibercept intravitreal injections once per month for the first 3 months (M0, M1, M2), then every 2 months (M4, M6, M8, M10)

DRUG

Aflibercept monthly

2.0mg aflibercept intravitreal injections every month (M0-11)

Sponsors & Collaborators

Principal Investigators

  • Prabakar K Rao, MD · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2019-01-31
Completion
2019-03-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01579760 on ClinicalTrials.gov